Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - PAREXEL International (NasdaqNM:PRXL)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 16Conference call: Parexel International Earnings (Q4 2001)
Aug 16Earnings Announcement
Location
195 West Street
Waltham, MA 02451
Phone: (781) 487-9900
Fax: (781) 487-9931
Email: kate.mccorriston@parexel.com
Employees (last reported count): 4,200
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 600 SmallCap
Ownership
·Insider and 5%+ Owners: 20%
·Over the last 6 months:
 · one insider buy; 2,000  shares
 · one insider sell; 15.0K shares
  (0.3% of insider shares)
·Institutional: 83% (104% of float)
(217 institutions)
·Net Inst. Buying: 1.03M shares (+4.78%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
PAREXEL International Corporation is a contract research, medical marketing and consulting services organization providing a broad spectrum of services from first-in-human clinical studies through product launch to the pharmaceutical, biotechnology and medical device industries around the world. The Company's service offerings include clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. PAREXEL has internally organized its operations into three interactive business units, Contract Research Services, Medical Marketing Services and Consulting Services.
More from Market Guide: Expanded Business Description

Financial Summary
PRXL is a contract research organization, providing product development and product launch services to the pharmaceutical, biotechnology, and medical device industries. For the nine months ended 3/31/01, revenues fell 2% to $280.9 million. Net income fell 9% to $2.8 million. Revenues reflect the contract cancellations and decreased Perceptive income. Net income reflects increased direct costs, higher staffing, training, retention and facility related expenses.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 106,699; after tax earnings were -3,580. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Josef Von Rickenbach, 45
Chairman, CEO
$387K
Carl Spalding
Pres, COO
--  
James Winschel, 51
CFO, Sr. VP
--  
Andrew Morffew, Ph.D., 50
Pres, PAREXEL Consulting Group
224K
Barry Philpott, 51
Pres of Clinical Research Services
253K
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:PRXLAs of 31-Aug-2001
Price and Volume
52-Week Low
on 2-Oct-2000
$8.063
Recent Price$14.25 
52-Week High
on 29-June-2001
$20.00 
Beta0.89 
Daily Volume (3-month avg)167.6K
Daily Volume (10-day avg)165.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+42.5%
52-Week Change
relative to S&P500
+91.2%
Share-Related Items
Market Capitalization$350.9M
Shares Outstanding24.6M
Float19.7M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 24-Feb-1997
Per-Share Data
Book Value (mrq*)$7.43 
Earnings (ttm)-$0.04 
Earnings (mrq)-$0.15 
Sales (ttm)$15.74 
Cash (mrq*)$2.62 
Valuation Ratios
Price/Book (mrq*)1.92 
Price/EarningsN/A 
Price/Sales (ttm)0.91 
Income Statements
Sales (ttm)$387.6M
EBITDA (ttm*)$21.4M
Income available to common (ttm)-$825.0K
Profitability
Profit Margin (ttm)-0.2%
Operating Margin (ttm)0%
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-0.23%
Return on Equity (ttm)-0.45%
Financial Strength
Current Ratio (mrq*)1.70 
Debt/Equity (mrq*)0.00 
Total Cash (mrq)$0 
Short Interest
As of 8-Aug-2001
Shares Short1.23M
Percent of Float6.3%
Shares Short
(Prior Month)
1.15M
Short Ratio13.13 
Daily Volume94.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.